Roivant Sciences (ROIV) Return on Capital Employed (2021 - 2025)
Roivant Sciences (ROIV) reported Return on Capital Employed of 25.77% for Q4 2025, down 10354.0% on a YoY basis from N/an in Q4 2024, and down 4.89% quarter-over-quarter from 24.57% in Q3 2025.
Roivant Sciences (ROIV) Return on Capital Employed (2021 - 2025) Analysis & Trends
Roivant Sciences has reported Return on Capital Employed for 5 years, with the latest figure at 25.77% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed fell 10354.0% year-over-year to 25.77%; the trailing twelve-month figure through Dec 2025 stood at 25.77% (down 10354.0% YoY), and the FY2026 full-year result was 9.93%, up 843.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 25.77%, down from 24.57% in the prior quarter.
- The five-year high for Return on Capital Employed was 97.28% in Q4 2023, with the low at 68.6% in Q3 2022.
- Historically, Return on Capital Employed has averaged 12.68% across 5 years, with a median of 29.59% in 2021.
- Annual changes were most pronounced in 2023 — Return on Capital Employed surged 15770 bps — and 2025, when it plunged 10354 bps.
- Roivant Sciences' Return on Capital Employed stood at 48.16% in 2021, then slipped by 25 bps to 60.42% in 2022, then surged by 261 bps to 97.28% in 2023, then declined by 20 bps to 77.77% in 2024, then tumbled by 133 bps to 25.77% in 2025.
- The last three Return on Capital Employed figures came in at 25.77% (Q4 2025), 24.57% (Q3 2025), and 19.59% (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Roivant Sciences | 21.82 Bn | 22.59 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -25.77% |
| Sep 30, 2025 | -24.57% |
| Jun 30, 2025 | -19.59% |
| Dec 31, 2024 | 77.77% |
| Sep 30, 2024 | 77.13% |
| Jun 30, 2024 | 68.25% |
| Dec 31, 2023 | 97.28% |
| Sep 30, 2023 | -62.61% |
| Jun 30, 2023 | -60.33% |
| Dec 31, 2022 | -60.42% |
| Sep 30, 2022 | -68.60% |
| Jun 30, 2022 | -60.39% |
| Dec 31, 2021 | -48.16% |
| Sep 30, 2021 | -50.68% |
| Jun 30, 2021 | -29.59% |